The brands in question are Paracetamol Bluepharma 1000mg, Paracetamol Sandoz 500 mg, Supofen tablets 1000 mg and Mwetformina Mylan.
In a statement the national authority explained: “Following an inspection by Infarmed of the manufacturer of medicinal products for human use Granules India Ltd. (Gagillapur, India), nonconformities were detected in the system of good manufacturing practices related to the granulation and primary packaging of tablets.”
The information was published by news site Notícias ao Minuto, and stressed that patients currently taking the aforementioned drugs should not interrupt treatment, but should see their doctor to be prescribed alternative medications.
Entities that have the drugs in stock are forbidden from selling, dispensing or administering them and should return them to suppliers.